
Journal of Medicinal Chemistry p. 1496 - 1504 (1990)
Update date:2022-08-04
Topics:
Reiffen
Eberlein
Muller
Psiorz
Noll
Heider
Lillie
Kobinger
Luger
Structural modification of the calcium-antagonist verapamil (1) by replacement of the lipophilic α-isopropylacetonitrile moiety by various heterocyclic ring systems has led to a new class of cardiovascular compounds which are characterized by a specific bradycardic activity. These agents reduce heart rate without binding to classical calcium channels or β-adrenoceptors, interacting instead specifically with structures at the sino atrial node. Therefore they have also been termed sinus node inhibition. The prototype falipamil (2) has been submitted to furthr optimization mainly hy manipulation of the phthalimidine moiety. This has resultd in a secod generation of specific bradycardic agents with increased potency and selectively and prolonged duration of action represented by the benzazepinone-derivative UL-FS 49 (4). Structure-activity relationships within this novel class of compounds have revealed a marked dependence of activity on the substitution pattern of the aromatic rings, the nature of the central nitrogen atom, and the length of the connecting alkyl chains. The crucial role of the benzazepione ring for bradycardic activity can be best explained by its special impact on the overall molecular conformation.
View MoreHangzhou Ocean Chemical Co., Ltd.
website:http://www.hzoceanchem.com
Contact:+86-571-88025872, 28272092, 28272096
Address:Room 623 ,Building No 1 , COFCO Radius Commercial Center Xiwen Road, Xiacheng District, Hangzhou, Zhejiang Province, China
KA-SHING Business Trade Macau Co., Ltd.
Contact:00853-28430045
Address:23rd Floor, Block 3 La Cite, Areia Preta, Macao
Anhui Redstar Pharmaceutical Corp., Ltd
Contact:+86-563-5120837
Address:Jingxian Industrial Development Zone, Anhui , China
Contact:+86-15850770348
Address:51 OF XIANGFANGCUN ROAD, Nanjing 210002, China
Contact:+86-25-85281586
Address:13F,Bld2#,South of Longpan Road
Doi:10.1071/CH03164
(2004)Doi:10.7164/antibiotics.31.933
(1978)Doi:10.1002/ejoc.200300649
(2004)Doi:10.1021/jm030354b
(2004)Doi:10.1021/jm00210a036
(1978)Doi:10.1002/ejoc.200300645
(2004)